Heart failure & cardiomyopathies
Race Comparisons in Patients With Cardiac Sarcoidosis: Insights From the Cardiac Sarcoidosis Consortium
Authors' conclusion
Black patients with cardiac sarcoidosis exhibited significantly higher rates of lung, skin, and eye involvement and comorbidities, but had similar cardiac clinical outcomes and all-cause mortality compared with White patients. Nonetheless, ascertainment bias cannot be excluded.
Study context
- Population
- Patients with cardiac sarcoidosis in the Cardiac Sarcoidosis Consortiumpatients included in the study
- Participants
- 619 patients
- Exposure
- Black versus White patients with cardiac sarcoidosis
- Blackn = 193
- Whiten = 362
- Other racesn = 64
- Outcome
- Composite of:
- All-cause mortality
- Left ventricular assist device implantation
- Heart transplantation
- Implantable cardioverter defibrillator therapy
Methodological detailsover 25 centers
- Over 25 centers
Main finding
As reported in the abstract
P = 0.79
Observational data: associations, not effects.
Further findings
| Outcome | Black | White | P value |
|---|---|---|---|
| Age at diagnosis of cardiac sarcoidosisBlack vs White · younger in Black patients · mean, years old | 50.5 (SD 11.8) | 53.7 (SD 10.5) | P = 0.010 |
| Left ventricular ejection fractionBlack vs White · lower in Black patients · mean | 44.6 (SD 15.4) | 48.3 (SD 14.0) | P = 0.008 |
| Extracardiac involvement (lungs, skin, eyes)More prevalent in Black patients | |||
| Lungs | 80.3% | 72.7% | |
| Skin | 22.8% | 12.4% | |
| Eyes | 13.5% | 5.5% | |
| Comorbidities | |||
| Hypertension | 69.9% | 50.6% | |
| Diabetes | 37.8% | 21.0% | |
| Smoking | 40.9% | 26.8% | |
| Chronic obstructive pulmonary disease or emphysema | 15.5% | 4.1% | |
| Chronic kidney disease | 25.9% | 12.4% | |
| Treatment patterns | |||
| Glucocorticoid | 71% | 74.3% | |
| Glucocorticoid-sparing | 53.4% | 59.9% | |
| Implantable cardioverter defibrillator or cardiac resynchronization implantation | 75.6% | 73.8% | |
| Primary outcome by left ventricular ejection fraction (subgroup) | |||
| LVEF >35% | 24.1% | 25.9% | |
| LVEF ≤35% | 51% | 42.5% |
- Extracardiac involvement (lungs, skin, eyes): lungs P =0.046
- Extracardiac involvement (lungs, skin, eyes): skin p =0.002
- Extracardiac involvement (lungs, skin, eyes): eyes P =0.001
- Comorbidities: each P <0.001
- Comorbidities: group order not labelled in the sentence; presented as Black versus White per conclusion
- Treatment patterns: glucocorticoid P =0.4
- Treatment patterns: glucocorticoid-sparing P =0.14
- Treatment patterns: ICD or CRT P =0.63
- Primary outcome by left ventricular ejection fraction (subgroup): LVEF >35% P =0.72
- Primary outcome by left ventricular ejection fraction (subgroup): LVEF ≤35% P =0.35
Treatment patterns
- Similar
Primary outcome by left ventricular ejection fraction (subgroup)
- No significant differences
Original publication
Race Comparisons in Patients With Cardiac Sarcoidosis: Insights From the Cardiac Sarcoidosis Consortium. Circ Arrhythm Electrophysiol. Published 25 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →